Publications by authors named "Neil Clendeninn"

Claim this Profile
H
HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Thomas Ottoboni, Michael Lauw, Mary Rose Keller, Matt Cravets, Kimberly Manhard, Neil Clendeninn

Future Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
Ralph Boccia, Robert B Geller, Neil Clendeninn, Thomas Ottoboni

Future Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Tom Ottoboni, Michael Lauw, Mary Rose Keller, Matt Cravets, Kimberly Manhard, Neil Clendeninn

Future Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
Tom Ottoboni, Mary Rose Keller, Matt Cravets, Neil Clendeninn, Barry Quart

Drug Des Devel Ther· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Alex A Adjei, Donald A Richards, Anthony El-Khoueiry, Fadi Braiteh, Carlos H R Becerra, Neil J Clendeninn

Clin Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Colin D Weekes, Daniel D Von Hoff, Alex A Adjei, Diane P Leffingwell, S Gail Eckhardt, Neil J Clendeninn

Clin Cancer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.
Minaxi Jhawer, Lee Rosen, Janet Dancey, Howard Hochster, Solomon Hamburg, Neil Clendeninn

Invest New Drugs· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.
Kenneth R Hande, Mary Collier, Linda Paradiso, Jill Stuart-Smith, Mary Dixon, Neil Clendeninn

Clin Cancer Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis